Skip to main content

Genotyping Assay Market to reflect impressive growth in Biotechnology Industry

 The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing. The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years.

What the Genotyping Assay Market Looks Like?

MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (CAGR) of 22.0% during the forecast period. North America is the largest regional market for glycomics

On the basis of application, the genotyping market is segmented into pharmacogenomics, diagnostics & personalized medicine, agricultural biotechnology, animal genetics, and other applications. The pharmacogenomics segment is expected to account for the largest share of the genotyping market during the forecast period. The large share of this segment can be attributed to the increasing use of genotyping to predict the efficiency of drugs during drug development and the growing need to understand the adverse effects of drugs.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595


What Drives the Genotyping Assay Market?

The growth of the global market Genotyping Assay Market is primarily influenced by the following factors:

  • Technological Advancements and Decreasing Prices of DNA Sequencing
  • Increasing Incidence of Genetic Diseases and Rising Awareness on Personalized Medicine
  • Growing Importance of Genotyping in Drug Development
  • Increasing Demand for Bioinformatics Solutions in Data Analysis

Among the product & service, segment, the reagents and kits segment is expected to grow at the highest CAGR during the forecast period. The factors attributing to the high growth are, the accessibility of a wide range of reagents, the increasing demand for reagents owing to the increasing genotyping test volumes across the globe, and the relatively smaller capital investment required to adopt reagents and kits for genotyping in pharmaceuticals and diagnostic centers.

The sequencing segment is expected to witness a faster growth rate in this market due to factors such as, the increasing application areas of DNA sequencing technologies, technological advancements, the availability of high-speed sequencing instruments, and the growing uptake of the hybrid approach of sequencing.

Recent Developments

  • In June 2019, Agilent Technologies (US) has launched InfinityLab LC/MSD iQ System
  • In June 2018, Thermo Fisher Scientific (US) had launched UHMR Hybrid Quadrupole-Orbitrap Mass Spectrometer.

Geographical growth scenario of Genotyping Assay Market:

North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region, along with an increasing demand from pharmaceutical companies for genotyping products and rising investments by government bodies, are responsible for the large share of the North American genotyping market.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595

Leading market players and strategies adopted

Illumina (US), Thermo Fisher Scientific (US), QIAGEN (Netherlands), Agilent Technologies (US), Danaher Corporation (US), Roche Diagnostics (Switzerland), GE Healthcare (US), Fluidigm Corporation (US), PerkinElmer (US), Eurofins Scientific (Luxembourg), Bio-Rad Laboratories (US), Pacific Biosciences of California (US), GENEWIZ (US), and Integrated DNA Technologies (US).

Illumina is the leading player in the genotyping market. The company led the sequencing market with its flagship NGS platforms—iSeq 100 system (launched in January 2018), NovaSeq 6000, HiSeq Series, MiSeq Series, NextSeq 500, and HiSeq X Ten & HiSeq X Five. Illumina also provides reagents such as TruSeq sample preparation kits, TruSeq SBS sequencing kits, and other sequencing reagents, along with sequencing services such as whole-genome sequencing, human whole-exome sequencing, de novo sequencing, custom-targeted resequencing, gene expression using random-primed RNA sampling, and other related services.

Labels:

Comments

Post a Comment

Popular posts from this blog

Autoinjectors Market | Newest Industry Data, Future Trends and Forecast 2023

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs. The  global autoinjectors market  is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023). In terms of Therapy, the global autoinjectors market can be segmented into: Rheumatoid Arthritis Multiple Sclerosis Diabetes Anaphylaxis Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia) By therapy, the rheumatoid arthritis segment is expected to account for the largest share of the market in 2018 On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therap...
Post a Comment
Read more

Medical Device Reprocessing Market – Statistics and Growth Dynamics To 2022

  Expected Revenue Growth: The  global medical device reprocessing market  is projected to be valued at USD 823.5 Million in 2017 and is expected to grow at a CAGR of 16.3% during the forecast period to reach to USD 1,754 Million by 2022. Base year considered for the report is 2016. What This Report Will Provide? The growth of this market is majorly driven by the increased utilization of the low priced reprocessed medical devices as compared to new devices, increased efforts towards reducing regulated medical waste (RMW), and rising number of surgical procedures associated with the growing prevalence of chronic diseases. However, the risk of transmission of surgical site infections associated with the use of reprocessed devices may hinder the growth of the market to a certain extent. Major Growth Boosters: The medical device reprocessing includes cleaning, disinfection, inspection, sterilization, and repackaging of used medical devices for its reuse to diagnose and treat ...
Post a Comment
Read more

Transplant Diagnostics Market Worth USD 5.5 Billion : Technological Advancements In The Field Of Transplant Diagnostics

  What This Report Will Provide? The study involved four major activities in estimating the current size of the transplant diagnostics market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Expected Revenue Growth: [227 Pages Report] The  transplant diagnostics market  is expected to reach USD 5.5 billion by 2025 from USD 3.6 billion in 2019, at a CAGR of 7.2%. Major Growth Boosters: The demand for transplant diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the increasing number of transplant procedures, and technological advancements in the field of transplant diagnostics. Download PDF Brochure:  https://www.marketsandmarkets.com/pd...
Post a Comment
Read more